Ex Vivo Metrics™, a preclinical tool in new drug development

被引:5
|
作者
Curtis, C. Gerald [1 ]
Bilyard, Kevin [2 ]
Stephenson, Hugo
机构
[1] Bowman Res Inc, Des Plaines, IL USA
[2] Nine TZ Healthcare Ventures, Post House, Congleton, Cheshire, England
关键词
Drug Development; Drug Candidate; Human Organ; Translational Medicine; Drug Development Process;
D O I
10.1186/1479-5876-6-5
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Among the challenges facing translational medicine today is the need for greater productivity and safety during the drug development process. To meet this need, practitioners of translational medicine are developing new technologies that can facilitate decision making during the early stages of drug discovery and clinical development. Ex Vivo Metrics (TM) is an emerging technology that addresses this need by using intact human organs ethically donated for research. After hypothermic storage, the organs are reanimated by blood perfusion, providing physiologically and biochemically stable preparations. In terms of emulating human exposure to drugs, Ex Vivo Metrics is the closest biological system available for clinical trials. Early application of this tool for evaluating drug targeting, efficacy, and toxicity could result in better selection among promising drug candidates, greater drug productivity, and increased safety.
引用
收藏
页数:5
相关论文
共 50 条
  • [21] Circulating tumor cells and CDX models as a tool for preclinical drug development
    Lallo, Alice
    Schenk, Maximilian W.
    Frese, Kristopher K.
    Blackhall, Fiona
    Dive, Caroline
    TRANSLATIONAL LUNG CANCER RESEARCH, 2017, 6 (04) : 397 - 408
  • [22] Development of an ex vivo porcine skin model for the preclinical evaluation of subcutaneously injected biomacromolecules
    Gou, Si
    Lapteva, Maria
    Brusini, Romain
    Flegeau, Killian
    Bourdon, Francois
    Kaya, Gurkan
    Faivre, Jimmy
    Kalia, Yogeshvar N.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2023, 648
  • [23] Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development
    Peterson, JK
    Houghton, PJ
    EUROPEAN JOURNAL OF CANCER, 2004, 40 (06) : 837 - 844
  • [24] A panel of xenograft models representative for human prostate cancer as a useful tool in the field of new drug development and preclinical drug testing
    van Weerden, WM
    de Ridder, CMA
    Romijn, JC
    van Steenbrugge, GJ
    Schroder, FH
    ANNALS OF ONCOLOGY, 1998, 9 : 39 - 39
  • [25] Ex Vivo Induction of mRNA in Human Whole Blood as a New Platform of Drug and Dietary Supplement Development
    Masato Mitsuhashi
    Mieko Ogura
    Katsuya Endo
    Kazuhiko Obara
    Hiroshi Izutsu
    Stephan R. Targan
    Motoko Maemura
    Daisuke Tachikawa
    Atsushi Shinagawa
    Pharmaceutical Research, 2008, 25 : 1116 - 1124
  • [26] Ex vivo induction of mRNA in human whole blood as a new platform of drug and dietary supplement development
    Mitsuhashi, Masato
    Ogura, Mieko
    Endo, Katsuya
    Obara, Kazuhiko
    Izutsu, Hiroshi
    Targan, Stephan R.
    Maemura, Motoko
    Tachikawa, Daisuke
    Shinagawa, Atsushi
    PHARMACEUTICAL RESEARCH, 2008, 25 (05) : 1116 - 1124
  • [27] Ex vivo simulation of drug action: Quantification of drug-induced mRNA as a bridge between preclinical and clinical trials
    Mitsuhashi, Masato
    CLINICAL CHEMISTRY, 2007, 53 (01) : 148 - 149
  • [28] Ex vivo nail infection as an effective preclinical method for screening of new topical antifungals
    Quatrin, P. M.
    Kaminski, T. F. A.
    Berlitz, S. J.
    Guerreiro, I. C. K.
    Canto, R. F. S.
    Fuentefria, A. M.
    JOURNAL DE MYCOLOGIE MEDICALE, 2020, 30 (02):
  • [29] BASIC ASPECTS OF HUMAN MILK OLIGOSACCHARIDES; NEW PRECLINICAL AND EX-VIVO OBSERVATIONS
    Prieto, P.
    Goehring, K.
    Davis, S.
    Bienenstock, J.
    Buck, R.
    ANNALS OF NUTRITION AND METABOLISM, 2013, 63 : 106 - 106
  • [30] PRECLINICAL DRUG DEVELOPMENT
    Brodniewicz, Teresa
    Grynkiewicz, Grzegorz
    ACTA POLONIAE PHARMACEUTICA, 2010, 67 (06): : 578 - 585